Friess Associates
PLXP

Friess Associates’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Friess Associates’s Portfolio PLXP Stock Details PLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-278,071
Closed -$2.23M – 126
2021
Q4 		$2.23M Sell
278,071
-98,487
-26% -$1.15M 0.87% 57
2021
Q3 		$7.27M Buy
376,558
+13,636
+4% +$238K 3.06% 4
2021
Q2 		$5.01M Buy
362,922
+59,522
+20% +$705K 1.89% 16
2021
Q1 		$2.74M Buy
+303,400
New +$2.22M 1.07% 38

Other funds holding PLXP

MSD Partners
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
Park West Asset Management
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Private Wealth Advisors
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Friess Associates's PLXP Position: Q1 2022 in Review

Friess Associates sold out of PLx Pharma Inc. Common Stock (PLXP) in Q1 2022, closing a stake of 278,071 shares — an estimated $2.23M sold.

Friess Associates first reported a position in PLXP in Q1 2021 and held it in 4 quarters. The position peaked at $7.27M in Q3 2021. 50 funds tracked by Wall St. Rank hold PLXP as of Q1 2022.

  • Friess Associates reported no remaining PLx Pharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Friess Associates sold 278,071 PLx Pharma Inc. Common Stock shares in Q1 2022, an estimated $2.23M.
  • Friess Associates first reported a position in PLx Pharma Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • Friess Associates's PLx Pharma Inc. Common Stock position peaked at $7.27M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q1 2022.

Based on Friess Associates's 13F filing for Q1 2022, filed 12 May 2022.